ENSG00000117862 (TXNDC12)

homo sapiens

thioredoxin domain containing 12

Filter your results

Homo sapiens
Organism part
Showing 9 experiments:
image/svg+xml human body features 2009-05-27 Sjef text : Kevin (tsaitgaist) REDON http://commons.wikimedia.org/wiki/File:Human_body_features.svg cerebral cortex pleura brain heart breast thyroid gland adrenal gland lymph node bone marrow adipose tissue skeletal muscle leukocyte frontal cortex temporal lobe prefrontal cortex pituitary gland atrial appendage aorta coronary artery gastroesophageal junction left ventricle hippocampus hippocampus caecum ileum rectum nose tongue left atrium pulmonary valve mitral valve penis vas deferens seminal vesicle testis epididymis eye nasal septum oral cavity tonsil nasal pharynx lung spinal cord amygdala trachea throat bronchus tricuspid valve diaphragm liver stomach spleen duodenum gall bladder pancreas colon small intestine appendix smooth muscle urinary bladder prostate gland nerve cerebellum cerebellar hemisphere kidney renal cortex bone cartilage esophagus salivary gland parotid gland submandibular gland skin
Created with Highcharts 6.2.0adiposebraindorsal thalamusgall bladderlungovarysalivary glandtelencephalonvermiform appendixanimal ovaryatrium auricular regioncerebellar hemispherecolonendometriumfallopian tubehippocampal formationleft cardiac atriummiddle frontal gyrusnucleus accumbenspineal bodyprostate glandskinstomachtibial arteryurinary bladder
T
GTEX - organism part
T
32 Uhlen's Lab
T
Mammalian Kaessmann
T
Hallstrom et al., 2014 - Organism part
T
Illumina Body Map
T
HDBR developing brain - 14 post …
T
HDBR developing brain - 10 post …
T
ENCODE (M. Snyder lab)
T
68 FANTOM5 project - adult
P
Proteomics
T
Transcriptomics
High
Medium
Low
Below cutoff
No data available

Filter your results

Kingdom
Species
Experiment type
Experimental variables
Regulation
-0.8
-2.7
0.6
2.4
Display log2-fold change
Download results
Log2-fold changeSpeciesGene nameComparisonExperimental variablesExperiment name
Adjusted p-valueLog2-fold change
5.4991 × 10-3-2.7
TXNDC12'P0 cells' vs 'untreated P4 cells'passage, treatmentTranscription profiling by high throughput sequencing of human fetal differentiated P0 retinal pigment epithelial cells, mesenchymal P4 cells, and A-83-01 rescued P4 cells
Adjusted p-valueLog2-fold change
2.3524 × 10-8-2.4
TXNDC12'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; monoculture'cell type, growth condition, stimulusReactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin
Adjusted p-valueLog2-fold change
2.5975 × 10-32.4
TXNDC12'anti-m6A' vs 'none'treatmentTranscription profiling by high throughput sequencing in identification of m6A modified sequences in HepG2 cells
Adjusted p-valueLog2-fold change
1.3587 × 10-19-2
TXNDC12'DMSO' in 'stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '6 hour'compound, time, treatmentGPBAR1 agonism has a broad impact on blocking macrophage activation
Adjusted p-valueLog2-fold change
3.6137 × 10-18-1.9
TXNDC12'EX00000246; stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '6 hour'compound, time, treatmentGPBAR1 agonism has a broad impact on blocking macrophage activation
Adjusted p-valueLog2-fold change
8.0889 × 10-6-1.9
TXNDC12'3 h DRB 0 min 4sU' vs 'untreated'treatment4sUDRB-seq: measuring transcription elongation and initiation genomewide
Adjusted p-valueLog2-fold change
8.6307 × 10-6-1.9
TXNDC12'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; co-culture'cell type, growth condition, stimulusReactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin
Adjusted p-valueLog2-fold change
3.9249 × 10-231.6
TXNDC12'valproic acid; 15 millimolar' vs 'control' at '2 day'compound, sampling time pointRNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout.
Adjusted p-valueLog2-fold change
3.5705 × 10-131.6
TXNDC12'valproic acid; 15 millimolar' vs 'control' at '1 day'compound, sampling time pointRNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout.
Adjusted p-valueLog2-fold change
7.2149 × 10-91.5
TXNDC12'valproic acid; 15 millimolar' vs 'control' at '3 day'compound, sampling time pointRNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout.
Adjusted p-valueLog2-fold change
3.3511 × 10-51.5
TXNDC12'erythroleukemia; ZRSR2 shRNA' vs 'normal'disease, genotypeRNA-seq of bone marrow from patients with myelodysplastic syndrome
Adjusted p-valueLog2-fold change
1.0059 × 10-4-1.5
TXNDC12'BRD9 homozygous knockout' vs 'wild type'phenotypeRNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations
Adjusted p-valueLog2-fold change
3.2404 × 10-71.4
TXNDC12'xenografted under NOD-scid/IL2Rg-null mouse kidney capsule for 10 weeks' vs 'not applicable' in 'organoid culture in matrigel'growth condition, xenograftEpithelium-only cultured stem cells isolated from human pluripotent stem cell derived intestinal organoids grown in matrigel and alginate
Adjusted p-valueLog2-fold change
1.1204 × 10-41.4
TXNDC12'suberoylanilide hydroxamic acid' vs 'control'compoundVascular histone deacetylation by pharmacological HDAC inhibition [SAHA, RNA-seq]
Adjusted p-valueLog2-fold change
6.051 × 10-41.4
TXNDC12'trichostatin A; 500 nanomolar' vs 'control'compoundTranscription profiling by high throughput sequencing of human aortic endothelial cell treated with TSA
Adjusted p-valueLog2-fold change
1.9433 × 10-3-1.4
TXNDC12'24 hours with hMSC Osteogenic Bullet Kit' vs 'none' in 'polysome'fraction, protocolRNA-seq of total RNA from human adipose tissue stem cells induced to adipogenesis and osteogenesis for 24 hours
Adjusted p-valueLog2-fold change
3.0846 × 10-251.3
TXNDC12'CD3/CD28 beads' vs 'none' in 'none'stimulus, xenograftRNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs
Adjusted p-valueLog2-fold change
9.4955 × 10-12-1.3
TXNDC12'Hermes 3A; shMITF knockdown' vs 'Hermes 3A; control'cell line, phenotypeBRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq)
Adjusted p-valueLog2-fold change
1.7137 × 10-8-1.3
TXNDC12'6 hour' vs '0 hour' in 'MCF-10A-H1047R'cell line, timeKnock-in of PIK3CA-H1047R into MCF-10A
Adjusted p-valueLog2-fold change
8.3612 × 10-51.3
TXNDC12'squamous cell carcinoma' vs 'normal'block, diseaseRNA-seq of a panel of non-melanoma skin cancer lesions
Adjusted p-valueLog2-fold change
7.042 × 10-3-1.3
TXNDC12'lipopolysaccharide; 10 nanogram per milliliter' vs 'none'compoundTranscription profiling by high throughput sequencing of human monocytes treated with lipopolysaccharide
Adjusted p-valueLog2-fold change
3.8263 × 10-111.2
TXNDC12'doxorubicin; 100 nanomolar' vs 'none' in 'ZNF84 siRNA'RNA interference, compoundRNAseq of HCT116 p53KO cells transfected with siRNA silencing ZNF84 or negative control with either doxorubicin treatment or untreated, cultured 72h post-transfection
Adjusted p-valueLog2-fold change
2.0893 × 10-8-1.2
TXNDC12'doxycycline; 0.5 microgram per milliliter; Day 3 post Neurogenin induction' vs 'control'compound, treatmentRapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq)
Adjusted p-valueLog2-fold change
3.6219 × 10-61.2
TXNDC12'human intestinal organoids derived from H9 stem cells' vs 'Undifferentiated H9 Stem Cells'cell typeTranscriptional Profiling of human pluripotent stem cells and and derived tissues
Adjusted p-valueLog2-fold change
4.4454 × 10-4-1.2
TXNDC12'HDAC1 homozygous knockout' vs 'wild type'phenotypeRNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations
Adjusted p-valueLog2-fold change
7.4888 × 10-20-1.1
TXNDC12'RNH1 knockout' vs 'wild type genotype'genotypeExpression data from Ribonuclease Inhibitor (RI/Rnh1) deficient Human K562 cells
Adjusted p-valueLog2-fold change
6.3067 × 10-171.1
TXNDC12'MAGEA3 shRNA' vs 'scrambled shRNA'RNA interferenceRNA-seq of the human HCC cell line PLC5 after 72 hours treatment with either MAGEA3 shRNA or Scramble control
Adjusted p-valueLog2-fold change
2.7903 × 10-11-1.1
TXNDC12'EX00000246' vs 'none' in 'unstimulated' at '6 hour'compound, time, treatmentGPBAR1 agonism has a broad impact on blocking macrophage activation
Adjusted p-valueLog2-fold change
9.7598 × 10-9-1.1
TXNDC12'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none'compound, infect, stimulusRNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C.
Adjusted p-valueLog2-fold change
1.8504 × 10-71.1
TXNDC12'KLF17 overexpression' vs 'wild type' at '5 day'phenotype, timeRNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression
Adjusted p-valueLog2-fold change
3.426 × 10-6-1.1
TXNDC12'TIGAR knockdown' vs 'wild type'phenotypeRNA-seq of human cancer cell line OVCA420* following TIGAR knockdown with shRNA
Adjusted p-valueLog2-fold change
4.3691 × 10-3-1.1
TXNDC12'BLVRB homozygous knockout' vs 'wild type'phenotypeRNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations
Adjusted p-valueLog2-fold change
2.0642 × 10-111
TXNDC12'JQ1 (250 micromolar); ICG-001 (2.5 micromolar)' vs 'dimethyl sulfoxide'stimulusRNA-seq in HSJD-DIPG-007 cells treated with JQ1, ICG-001, JQ1 and ICG-001 and DMSO as control.
Adjusted p-valueLog2-fold change
2.2508 × 10-101
TXNDC12'injected in NSG-HLA-A2/HHD mouse' vs 'none' in 'none'stimulus, xenograftRNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs
Adjusted p-valueLog2-fold change
1.2766 × 10-8-1
TXNDC12'breast carcinoma' vs 'normal'block, diseaseRNA-seq of blood platelets from six tumor types and healthy donors
Adjusted p-valueLog2-fold change
2.4246 × 10-81
TXNDC12'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none'compound, infect, stimulusRNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C.
Adjusted p-valueLog2-fold change
8.5825 × 10-8-1
TXNDC12'non-small cell lung carcinoma' vs 'normal'block, diseaseRNA-seq of blood platelets from six tumor types and healthy donors
Adjusted p-valueLog2-fold change
1.2897 × 10-6-1
TXNDC12'doxycycline; 0.5 microgram per milliliter; Day 4 post Neurogenin induction' vs 'control'compound, treatmentRapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq)
Adjusted p-valueLog2-fold change
1.3258 × 10-61
TXNDC12'KLF17 overexpression' at '24 day' vs 'wild type' at '0 day'phenotype, timeRNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression
Adjusted p-valueLog2-fold change
7.4547 × 10-61
TXNDC12'apical radial glial cell' vs 'neuron'cell typeTranscription profiling by high throughput sequencing of the developing human cortex
Adjusted p-valueLog2-fold change
1.0074 × 10-51
TXNDC12'shSUZ12' vs 'control'RNA interferenceRNA-seq transcriptional profiling in primary human erythroid progenitor cells upon shRNA-mediated knockdown of PRC2 core subunits
Adjusted p-valueLog2-fold change
1.8016 × 10-31
TXNDC12'actinic keratosis' vs 'normal'block, diseaseRNA-seq of a panel of non-melanoma skin cancer lesions
Adjusted p-valueLog2-fold change
2.7251 × 10-3-1
TXNDC12'6 hour' vs '0 hour' in 'MCF-10A'cell line, timeKnock-in of PIK3CA-H1047R into MCF-10A
Adjusted p-valueLog2-fold change
2.7855 × 10-3-1
TXNDC12'DMSO; prostate carcinoma' at '24 hour' vs 'DMSO; normal' at '24 hour'compound, disease, timeGenome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells.
Adjusted p-valueLog2-fold change
3.1101 × 10-31
TXNDC12'pBABE-puro-H-RasG12V; senescent' vs 'control; proliferative'genotype, phenotypeTranscription profiling by high throughput sequencing of proliferative and Ras-induced senescent human primary fibroblasts
Adjusted p-valueLog2-fold change
5.1708 × 10-3-1
TXNDC12'sulforaphane; prostate carcinoma' at '6 hour' vs 'sulforaphane; normal' at '6 hour'compound, disease, timeGenome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells.
Adjusted p-valueLog2-fold change
1.5316 × 10-21
TXNDC12'induced into senescence; adriamycin' vs 'spontaneously immortal cells; control'phenotype, treatmentPathway Profiling of Replicative and Induced Senescence
Adjusted p-valueLog2-fold change
1.7624 × 10-21
TXNDC12'primary tumor' vs 'adjacent non-tumor colon' in 'colorectal cancer'disease, sampling siteRNA-seq of colorectal cancer primary tumor and adjacent colon tissue
Adjusted p-valueLog2-fold change
2.1434 × 10-2-1
TXNDC12'RIPK1 homozygous knockout' vs 'wild type'phenotypeRNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations
Adjusted p-valueLog2-fold change
6.1467 × 10-4-0.8
TXNDC12'clear cell renal cell carcinoma' vs 'normal'diseaseSWATH analysis of human kidney tissues to generate a digital map representing the proteome of biopsy level clinical samples.
Adjusted p-valueLog2-fold change
1.0997 × 10-30.6
TXNDC12'intravascular lymphoma' vs 'diffuse large B-cell lymphoma'disease113 DLBCL SWATH maps by PCT-SWATH